Answers are grounded in this paper and cite their sources.
Biosimilars are highly similar versions of reference biological products, some with the potential to be deemed 'interchangeable' by regulatory bodies, such as the US Food and Drug Administration. Biosimilar patent litigation continues to evolve as biosimilars enter new global markets. This manuscript takes a
No takes yet. Share an insight, caveat, or question.
Brian J Malkin (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: